Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Cell

• Publication date

  2017-10-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2017.09.011PMID 29017052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.

  2018cited by this paper
• Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?

  2018cited by this paper
• Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

  2017cited by this paper
• Multipotent Basal Stem Cells, Maintained in Localized Proximal Niches, Support Directed Long-Ranging Epithelial Flows in Human Prostates

  2017cited by this paper
• Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

  2017influential reference
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

  2015cited by this paper
• Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β‐catenin/TCF‐4 complex inhibition of c‐MYC transcription

  2014cited by this paper
• Prostate cancer cell–stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases

  2014cited by this paper
• Loss of Androgen Receptor-Dependent Growth Suppression by Prostate Cancer Cells Can Occur Independently from Acquiring Oncogenic Addiction to Androgen Receptor Signaling

  2010cited by this paper
• Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

  2003cited by this paper
• The biology of hormone refractory prostate cancer. Why does it develop?

  1999cited by this paper
• Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats.

  1989cited by this paper

• Therapeutic interference of SREBP-mediated lipid metabolism by E-Xanthohumol attenuates prostate cancer progression.

  2026cites this paper
• Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors

  2025cites this paper
• MicroRNA-506 as a tumor suppressor in prostate cancer by regulation of Hippo signaling pathway

  2024cites this paper
• Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer

  2024cites this paper
• Molecular docking studies of YKT tripeptide and drug delivery system with poly(ε‐caprolactone) nanoparticles

  2022cites this paper
• Investigation of the effect of meclofenamic acid on the proteome of LNCaP cells reveals changes in alternative polyadenylation and splicing machinery

  2022cites this paper
• The FGF/FGFR System in the Physiopathology of the Prostate Gland.

  2020cites this paper
• Hormone -Refractory Prostatic Adenocarcinoma Mimicking Basal Cell Carcinoma: A Case Report

  2020cites this paper
• Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer

  2020cites this paper
• Long-Chain Acyl-CoA Synthetase 4–Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway–Independent Prostate Cancer

  2020cites this paper
• Activation of b-Catenin Cooperates with Loss of Pten to Drive AR-Independent Castration-Resistant Prostate Cancer

  2020cites this paper
• Cell Biology International

  2019influential citation
• Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications

  2019cites this paper
• Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer.

  2019cites this paper
• Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer

  2019cites this paper
• Long non-coding RNA SAP30L-AS1 promotes prostate cancer growth through repressing SAP30L.

  2019cites this paper
• Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.

  2018cites this paper
• Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?

  2018cites this paper
• Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain

  2018cites this paper
• Effects of exogenous lactoferrin on phenotypic profile and invasiveness of human prostate cancer cells (DU145 and LNCaP) in vitro.

  2018cites this paper
• Personalization of prostate cancer therapy through phosphoproteomics

  2018cites this paper